• Revenue **$11.12B (+5% YoY)**, organic **+3%**
• GAAP EPS **$4.27** (flat), **Adj. EPS $5.79 (+10%)**
• GAAP operating margin **17.4%**, **Adj. margin 23.3% (+100 bps)**
• Free cash flow **$1.84B** in the quarter
• Highlights: FDA approval for **Oncomine Dx Express**, launch of **Olink Target 48 Neurodegeneration**, new **Talos 12 TEM** system
• Deals: acquired **Solventum** Filtration & Separation, **Sanofi Ridgefield** fill-finish site; **$1.0B** share repurchase
• Tech: **strategic collaboration with OpenAI** to accelerate R&D productivity
• **Guidance update** to be provided on the earnings call (8:30 ET)